Hepatitis C virus: The importance of viral heterogeneity

Clinics in Liver Disease

Volumn 5, Issue 4, 2001, Pages 895-916

  Farci, Patrizia ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR IMMUNITY; CHIMPANZEE; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNITY; INFECTION PREVENTION; NONHUMAN; REVIEW; VIRUS CELL INTERACTION;

EID: 0034772636     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70200-2     Document Type: Article

References (143)

1. Hepatitis C virus, the E2 envelope protein, and α-interferon resistance
2. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: Studies of infected donor-recipient clusters
3. Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response
4. To C or not to C: These are the questions
5. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
6. The natural history of community-acquired hepatitis C in the United States
7. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees
8. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment
9. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
10. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
11. Immunological significance of cytotoxic T lymphocite epitope variants in patients chronically infected by the hepatitis C virus
12. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
13. Differential CD4 and CD8 T-cell responsiveness in hepatitis C virus infection
14. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
15. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy
16. Persistence of HCV despite antibodies to both putative evelope glycoproteins
17. Isolation of cDNA derived from bloodborne non-A, non-B viral hepatitis genome
18. Vaccination of chimpanzees against infection by the hepatitis C virus
19. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
20. Viral persistence in vivo through selection of neutralizing antibody-escape variants
21. Analysis of a successful immune response against hepatitis C virus
22. Factors predictive of a beneficial response to therapy of hepatitis C
23. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
24. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
25. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
26. High error rates, population equilibrium and evolution of RNA replication systems
27. Biological significance of viral quasispecies
28. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity
29. Self organization of matter and the evolution of biological macromolecules
30. Sequence space and quasispecles distribution
31. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b
32. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
33. Long-term study of hepatitis C virus replication in non-A, non-B hepatitis
34. Lack of protective immunity against reinfection with hepatitis C virus
35. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
36. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
37. Evolution of HCV quasispecies in the different patterns of response to interferon therapy in chronic hepatitis C
38. Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee
39. Clinical significance of hepatitis C virus genotypes and quasispecies
40. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
41. Tranfustion-associated hepatitis not due to viral hepatitis type A or B
42. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
43. How Escherichia coli can bias the results of molecular cloning: Preferential selection of defective genomes of hepatitis C virus during the cloning procedure
44. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees
45. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural A protein
46. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
47. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
48. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C
49. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha
50. Hepatitis C viral quasispecies
51. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C
52. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy
53. Treatment with recombinant interferon-alpha2a for patients with chronic hepatitis C: Predictive factors for biochemical and virologic response
54. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection
55. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: A prospective study
56. Mutations in the NS5A gene of hepatitis C virus in North American patients with HCV genotype 1a or 1b
57. Rapid evolution of RNA genomes
58. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease
59. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
60. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope
61. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis
62. Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis
63. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
64. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
65. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation
66. Viral escape and the failure of cellular immune responses
67. Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C
68. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment
69. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
70. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection
71. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood
72. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient
73. Analysis of genotypes and amino acid residues 2209-2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
74. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children
75. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus
76. Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in french patients with chronic hepatitis C
77. Hypervariable 5′-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants
78. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon
79. Analysis of hepatitis C virus quasispecies populations by temperature gradient gel electrophoresis
80. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus
81. Evolution of hypervariable region 1 of hepatitis C virus in primary infection
82. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
83. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
84. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
85. Differential sensitivity of hepatitis C virus quasispecies to interferon-therapy
86. Antibody responses to hepatitis C virus hypervariable region 1: Evidence for cross-reactivity and immune-mediated sequence variation
87. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy
88. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease
89. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy
90. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment
91. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus
92. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
93. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: Variability and stability
94. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a
95. Genetic heterogeneity of hepatitis C virus
96. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
97. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
98. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
99. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
100. Binding of hepatitis C virus to CD81
101. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: Correlation with response to interferon therapy
102. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection
103. Immunity in hepatitis C infection
104. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans
105. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy
106. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpazees
107. Interaction between the hepatitis C virus and the immune system
108. A quantitative test to estimate neutralizing antibodies to hepatitis C virus: Cytofluorometric assessment of envelope glycoprotein E2 binding to target cells
109. The prognostic relevance of the nonstructural A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
110. Selection of hepatitis C virus quasispecies during interferon treatment
111. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy
112. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response
113. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (E2; gp70) hypervariable region 1 in hepatitis C viremic patients
114. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease
115. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line
116. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutants
117. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures
118. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy
119. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
120. Mutations in the nonstructural A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
121. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hapatitis C virus-1b infection
122. Rapid evolution of RNA viruses
123. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus (E2/NS1) protein: Implication for an escape from antibody
124. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
125. Quasispecies nature of hepatitis C virus and response to alpha interferon: Significance as a predictor of direct response to interferon
126. Hepatitis C virus variants circumventing cytotoxic T-lymphocyte activity as a mechanism of chronicity
127. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune response
128. Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition
129. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
130. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins
131. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infection
132. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
133. Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: Correlation with nudeotide sequencing
134. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
135. Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-therapy
136. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies
137. Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load
138. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
139. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment
140. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus
141. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus